Diagnostic Usefulness of Monoclonal Antibody P504S in the Workup of Atypical Prostatic Glandular Proliferations

American Journal of Clinical Pathology

Volumn 120, Issue 5, 2003, Pages 737-745

  Kunju, Lakshmi P ^a   Rubin, Mark A ^b   Chinnaiyan, Arul M ^a   Shah, Rajal B ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

AMACR; P504S; Prostate cancer; Prostate needle biopsies; Methylacyl CoA racemase

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY P504S; UNCLASSIFIED DRUG;

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE ADENOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SENSITIVITY AND SPECIFICITY; STAINING; TRANSURETHRAL RESECTION;

EID: 0242332137     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/3T3Y0K0TUMYH3WY2     Document Type: Article

References (25)

1. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA. 1995;274:1445-1449.
2. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-1290.
3. Brawer MK, Peehl DM, Stamey TA, et al. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 1985;45:3663-3667.
4. O'Malley FP, Grignon DJ, Shum DT. Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchows Arch A Pathol Anat Histopathol. 1990;417:191-196.
5. Shah RB, Zhou M, LeBlanc M, et al. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol. 2002;26:1161-1168.
6. Wojno KJ, Epstein JI. The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer: a review of 228 cases. Am J Surg Pathol. 1995;19:251-260.
7. Bostwick DG, Srigley J, Grignon D, et al. Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol. 1993;24:819-832.
8. Bostwick DG, Algaba F, Amin MB, et al. Consensus statement on terminology: recommendation to use atypical adenomatous hyperplasia in place of adenosis of the prostate [letter]. Hum Pathol. 1994;25:840.
9. Gaudin PB, Reuter VE. Benign mimics of prostatic adenocarcinoma on needle biopsy. Anat Pathol. 1997;2:111-134.
10. Xu J, Stolk JA, Zhang X, et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 2000;60:1677-1682.
11. Luo J, Zha S, Gage WR, et al. alpha-Methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002;62:2220-2226.
12. Rubin MA, Zhou M, Dhanasekaran SM, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002;287:1662-1670.
13. Jiang Z, Woda BA, Rock KL, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol. 2001;25:1397-1404.
14. Beach R, Gown AM, de Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26:1588-1596.
15. Yang XJ, Wu CL, Woda BA, et al. Expression of alpha-methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol. 2002;26:921-925.
16. Jiang Z, Wu CL, Woda BA, et al. P504S/alpha-methylacyl CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol. 2002;26:1169-1174.
17. Rubin MA, Dunn R, Kambham N, et al. Should a Gleason score be assigned to a minute focus of carcinoma on prostate biopsy? Am J Surg Pathol. 2000;24:1634-1640.
18. Kuefer R, Varambally S, Zhou M, et al. alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol. 2002;161:841-848.
19. Zhou M, Chinnaiyan AM, Kleer CG, et al. alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol. 2002;26:926-931.
20. Epstein JI. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol. 1995;26:223-229.
21. Varma M, Morgan M, Amin MB, et al. High molecular weight cytokeratin antibody (clone 34betaE12): a sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer. Histopathology. 2003;42:167-172.
22. Chen L, Jiang Z, Woda BA, et al. Decreased expression of alpha-methylacyl-CoA-racemase in foamy gland carcinoma of prostate [abstract]. Mod Pathol. 2003;16:145.
23. Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methylacyl-CoA-racemase in foamy gland prostate cancer and pseudohyperplastic prostate cancer. Am J Surg Pathol. 2003;27:772-778.
24. Gupta N, de Peralta-Venturina M, Gown A, et al. P504S antibody expression in putative precursor lesions of prostate carcinoma: high grade prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia [abstract]. Mod Pathol. 2003;16:152.
25. Kunju LP, Rubin MA, Shen R, et al. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha-methylacyl-CoA racemase in benign, atypical and malignant prostate tissues [abstract]. Mod Pathol. 2003;16:718.